BioCentury
ARTICLE | Clinical News

ALKS 37: Development discontinued

June 4, 2012 7:00 AM UTC

Alkermes discontinued development of ALKS 37 after top-line data from a double-blind, placebo-controlled, U.S. Phase IIb trial in about 150 patients with OIC showed that ALKS 37's product profile did not satisfy undisclosed pre-specified criteria for advancing into Phase III trials. The company did say that patients receiving ALKS 37 experienced an increase in bowel movements compared to baseline. ALKS 37 was generally well tolerated. Alkermes said it will conclude a second Phase IIb trial of ALKS 37 in the indication and that it does not plan to conduct additional studies. The company also said it will consider out-licensing opportunities for the compound. ...